These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31902406)

  • 1. Renal Impairment, Cardiovascular Disease, and the Short-Term Efficacy and Safety of PCSK9 Targeted by Inclisiran.
    Zijlstra LE; Trompet S; Mooijaart SP; van Buren M; Jukema JW
    Mayo Clin Proc; 2020 Jan; 95(1):12-14. PubMed ID: 31902406
    [No Abstract]   [Full Text] [Related]  

  • 2. Inclisiran for the treatment of dyslipidemia.
    Nishikido T; Ray KK
    Expert Opin Investig Drugs; 2018 Mar; 27(3):287-294. PubMed ID: 29451410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
    Ray KK; Landmesser U; Leiter LA; Kallend D; Dufour R; Karakas M; Hall T; Troquay RP; Turner T; Visseren FL; Wijngaard P; Wright RS; Kastelein JJ
    N Engl J Med; 2017 Apr; 376(15):1430-1440. PubMed ID: 28306389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial.
    Leiter LA; Teoh H; Kallend D; Wright RS; Landmesser U; Wijngaard PLJ; Kastelein JJP; Ray KK
    Diabetes Care; 2019 Jan; 42(1):173-176. PubMed ID: 30487231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholesterol lowering with inclisiran: a new chapter in the PCSK9 story book.
    Santos RD; Rocha VZ
    Eur Heart J; 2023 Jan; 44(2):139-141. PubMed ID: 36331316
    [No Abstract]   [Full Text] [Related]  

  • 6. Inclisiran: a new milestone on the PCSK9 road to tackle cardiovascular risk.
    Santulli G; Jankauskas SS; Gambardella J
    Eur Heart J Cardiovasc Pharmacother; 2021 May; 7(3):e11-e12. PubMed ID: 33655296
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
    Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP
    Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?
    Hadjiphilippou S; Ray KK
    Heart; 2017 Nov; 103(21):1670-1679. PubMed ID: 28596304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inclisiran: A Game Changer in a Changing Game?
    Nambi V; Agha A
    J Am Coll Cardiol; 2021 Mar; 77(9):1194-1196. PubMed ID: 33663736
    [No Abstract]   [Full Text] [Related]  

  • 10. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
    Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New hope for hyperlipidemia management: Inclisiran.
    Bandyopadhyay D; Hajra A; Ashish K; Qureshi A; Ball S
    J Cardiol; 2018 May; 71(5):523-524. PubMed ID: 29174841
    [No Abstract]   [Full Text] [Related]  

  • 12. PCSK9 in context: A contemporary review of an important biological target for the prevention and treatment of atherosclerotic cardiovascular disease.
    Page MM; Watts GF
    Diabetes Obes Metab; 2018 Feb; 20(2):270-282. PubMed ID: 28736830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.
    Fitzgerald K; White S; Borodovsky A; Bettencourt BR; Strahs A; Clausen V; Wijngaard P; Horton JD; Taubel J; Brooks A; Fernando C; Kauffman RS; Kallend D; Vaishnaw A; Simon A
    N Engl J Med; 2017 Jan; 376(1):41-51. PubMed ID: 27959715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA Interference for the Masses? siRNA Targeting PCSK9 Promises Prevention of Cardiovascular Disease.
    Watts JK; Ockene IS
    Nucleic Acid Ther; 2020 Feb; 30(1):1-3. PubMed ID: 31928497
    [No Abstract]   [Full Text] [Related]  

  • 15. Emerging biologic therapies for hypercholesterolaemia.
    Pucci G; Cicero AF; Borghi C; Schillaci G
    Expert Opin Biol Ther; 2017 Sep; 17(9):1077-1087. PubMed ID: 28617192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program.
    Stoekenbroek RM; Kallend D; Wijngaard PL; Kastelein JJ
    Future Cardiol; 2018 Nov; 14(6):433-442. PubMed ID: 30375244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dyslipidaemia: Promising results with siRNA against PCSK9.
    Fernández-Ruiz I
    Nat Rev Cardiol; 2017 May; 14(5):252. PubMed ID: 28361974
    [No Abstract]   [Full Text] [Related]  

  • 18. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights from ORION studies: focus on inclisiran safety.
    Catapano AL; Pirillo A; Norata GD
    Cardiovasc Res; 2021 Jan; 117(1):24-26. PubMed ID: 32402083
    [No Abstract]   [Full Text] [Related]  

  • 20. Pleiotropic Anti-atherosclerotic Effects of PCSK9 InhibitorsFrom Molecular Biology to Clinical Translation.
    Karagiannis AD; Liu M; Toth PP; Zhao S; Agrawal DK; Libby P; Chatzizisis YS
    Curr Atheroscler Rep; 2018 Mar; 20(4):20. PubMed ID: 29525934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.